Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Receivables (2019 - 2023)

Summit Therapeutics (SMMT) has disclosed Change in Receivables for 5 consecutive years, with -$3000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Change in Receivables rose 99.76% year-over-year to -$3000.0, compared with a TTM value of -$3000.0 through Jun 2024, up 98.25%, and an annual FY2023 reading of -$359000.0, up 63.18% over the prior year.
  • Change in Receivables was -$3000.0 for Q3 2023 at Summit Therapeutics, up from -$6000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $3.5 million in Q3 2020 and bottomed at -$3.7 million in Q4 2020.
  • Average Change in Receivables over 5 years is -$193562.5, with a median of -$178000.0 recorded in 2023.
  • Peak annual rise in Change in Receivables hit 251.5% in 2022, while the deepest fall reached 499.12% in 2022.
  • Year by year, Change in Receivables stood at -$2.7 million in 2019, then tumbled by 37.3% to -$3.7 million in 2020, then skyrocketed by 74.76% to -$932000.0 in 2021, then soared by 251.5% to $1.4 million in 2022, then tumbled by 100.21% to -$3000.0 in 2023.
  • Business Quant data shows Change in Receivables for SMMT at -$3000.0 in Q3 2023, -$6000.0 in Q2 2023, and -$350000.0 in Q1 2023.